Ivonescimab · HARMONi-7
The sponsor lists the global first-line, PD-L1-high monotherapy study as enrolling. HARMONi, HARMONi-2 and HARMONi-7 are separate trials; positive data in the first two do not settle this study. ivonescimab — phase 3 study in Non-Small Cell Lung Cancer. NCT06767514 lists Overall Survival (OS) as a primary outcome (Up to approximately 36 months). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2028-04 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
- The registry lists 2 primary outcome measures. A market must explicitly specify which endpoint or conjunction resolves YES; this card highlights one measure only.
Primary evidence
Enrolling Phase 3 — result date unconfirmed
Potential outcome market
Will ivonescimab meet the prespecified primary endpoint in NCT06767514 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.